Dr. Reddy’s Laboratories Announces the Appointment of Mr. Bharat Doshi as an Additional Independent Director on the Board of the Company
HYDERABAD, India--(BUSINESS WIRE)-- Mr. Bharat Doshi has been appointed as an Additional Independent Director on the Board of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), effective May 11, 2016.
Mr. Bharat Doshi is a Fellow Member of the Institute of Chartered Accountants of India and of the Institute of Company Secretaries of India, and holds a Master’s degree in Law from Bombay University. He is an alumnus of Harvard Business School (PMD) and Fellow of the “Salzburg Seminar on Asian Economies: Regional and Global Relationships.”
Mr. Doshi is a former Executive Director and Group CFO of Mahindra & Mahindra Limited, the flagship company of the Mahindra Group. He was also the Chairman of Mahindra & Mahindra Financial Services Limited since April 2008 and he stepped down from this position on his nomination as director on the Central Board of Directors of the Reserve Bank of India in March 2016.
He is the Chairman of Mahindra Intertrade Limited, and a Director on the Board of Mahindra Holdings Limited. He is also an Independent Director of Godrej Consumer Products Limited.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may," "will," "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.
The company assumes no obligation to update any information contained herein.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160511006306/en/
Dr. Reddy’s Laboratories Ltd.
INVESTOR RELATIONS:
Kedar
Upadhye
+91-40-66834297
[email protected]
or
MEDIA
RELATIONS:
Calvin Printer
+91-40-49002121
[email protected]
Source: Dr. Reddy’s Laboratories Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NyquistAI - Advancing Beyond Data to AI Transformation for Life Sciences
- GenScript Singapore's Open Day Reveals Pioneering AI Capabilities in Recombinant Protein Production and Drug Discovery
- ZeroAvia Launches Electric and Hydrogen Aviation Components Offering as Manufacturing Plans Revealed
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!